Cercano Management LLC Raises Stock Holdings in DexCom, Inc. (NASDAQ:DXCM)

Cercano Management LLC boosted its stake in DexCom, Inc. (NASDAQ:DXCM) by 4.5% during the 4th quarter, Holdings Channel reports. The institutional investor owned 213,068 shares of the medical device company’s stock after acquiring an additional 9,108 shares during the period. Cercano Management LLC’s holdings in DexCom were worth $26,440,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Stableford Capital II LLC boosted its holdings in DexCom by 2.1% in the fourth quarter. Stableford Capital II LLC now owns 4,367 shares of the medical device company’s stock valued at $563,000 after purchasing an additional 88 shares in the last quarter. Valley National Advisers Inc. boosted its holdings in shares of DexCom by 73.0% in the fourth quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock valued at $30,000 after acquiring an additional 103 shares during the period. FORVIS Wealth Advisors LLC boosted its holdings in shares of DexCom by 0.7% in the fourth quarter. FORVIS Wealth Advisors LLC now owns 16,381 shares of the medical device company’s stock valued at $2,033,000 after acquiring an additional 110 shares during the period. Cary Street Partners Investment Advisory LLC boosted its holdings in shares of DexCom by 11.1% in the third quarter. Cary Street Partners Investment Advisory LLC now owns 1,153 shares of the medical device company’s stock valued at $108,000 after acquiring an additional 115 shares during the period. Finally, HM Payson & Co. boosted its holdings in shares of DexCom by 8.5% in the third quarter. HM Payson & Co. now owns 1,480 shares of the medical device company’s stock valued at $138,000 after acquiring an additional 116 shares during the period. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

DXCM has been the subject of several research analyst reports. Royal Bank of Canada initiated coverage on DexCom in a report on Tuesday, March 12th. They issued an “outperform” rating and a $165.00 price objective for the company. StockNews.com downgraded DexCom from a “buy” rating to a “hold” rating in a report on Tuesday, April 23rd. UBS Group increased their price objective on DexCom from $153.00 to $163.00 and gave the company a “buy” rating in a report on Wednesday, April 10th. Citigroup upped their price target on DexCom from $148.00 to $161.00 and gave the stock a “buy” rating in a research note on Wednesday, April 3rd. Finally, Canaccord Genuity Group lifted their price objective on shares of DexCom from $144.00 to $145.00 and gave the company a “buy” rating in a research report on Friday. Three analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $141.67.

Insider Buying and Selling at DexCom

In other news, EVP Matthew Vincent Dolan sold 1,990 shares of DexCom stock in a transaction on Monday, April 15th. The stock was sold at an average price of $137.81, for a total transaction of $274,241.90. Following the completion of the transaction, the executive vice president now owns 42,377 shares of the company’s stock, valued at approximately $5,839,974.37. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other news, EVP Michael Jon Brown sold 2,624 shares of DexCom stock in a transaction on Thursday, March 28th. The stock was sold at an average price of $140.04, for a total transaction of $367,464.96. Following the completion of the transaction, the executive vice president now owns 68,682 shares of the company’s stock, valued at approximately $9,618,227.28. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Matthew Vincent Dolan sold 1,990 shares of DexCom stock in a transaction on Monday, April 15th. The stock was sold at an average price of $137.81, for a total value of $274,241.90. Following the transaction, the executive vice president now directly owns 42,377 shares of the company’s stock, valued at approximately $5,839,974.37. The disclosure for this sale can be found here. Over the last quarter, insiders sold 189,375 shares of company stock valued at $25,530,859. 0.41% of the stock is owned by company insiders.

DexCom Price Performance

DexCom stock traded down $13.67 during midday trading on Friday, reaching $124.34. The company’s stock had a trading volume of 8,578,184 shares, compared to its average volume of 2,409,208. DexCom, Inc. has a fifty-two week low of $74.75 and a fifty-two week high of $142.00. The company has a debt-to-equity ratio of 1.18, a quick ratio of 2.48 and a current ratio of 2.84. The stock’s 50 day simple moving average is $131.13 and its 200 day simple moving average is $118.53. The firm has a market capitalization of $49.24 billion, a PE ratio of 80.22, a P/E/G ratio of 2.14 and a beta of 1.20.

DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, April 25th. The medical device company reported $0.32 EPS for the quarter, beating analysts’ consensus estimates of $0.27 by $0.05. DexCom had a return on equity of 31.38% and a net margin of 16.82%. The company had revenue of $921.00 million during the quarter, compared to the consensus estimate of $911.20 million. On average, equities research analysts forecast that DexCom, Inc. will post 1.78 earnings per share for the current year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.